Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions
Authors Kaja S, Shah A, Haji S, Patel K, Naumchuk Y, Zabaneh A, Gerdes B, Kunjukunju N, Sabates N, Cassell M, Lord R, Pikey K, Poulose A, Koulen P
Received 12 January 2015
Accepted for publication 17 February 2015
Published 7 April 2015 Volume 2015:9 Pages 611—618
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Scott Fraser
Simon Kaja,1,* Anna A Shah,1,* Shamim A Haji,1,* Krishna B Patel,1 Yuliya Naumchuk,1 Alexander Zabaneh,1 Bryan C Gerdes,1 Nancy Kunjukunju,1 Nelson R Sabates,1 Michael A Cassell,1 Ron K Lord,1 Kevin P Pikey,1 Abraham Poulose,1 Peter Koulen1,2
1Vision Research Center, Department of Ophthalmology, 2Department of Basic Medical Science, School of Medicine, University of Missouri – Kansas City, Kansas City, MO, USA
*These authors contributed equally to this work
Abstract: The main objective of the study was to quantify serum levels of nicotinamide phosphoribosyltransferase (Nampt/pre-B-Cell colony-enhancing factor 1/visfatin) in subjects with a history of retinal vascular occlusions (RVOs), disease conditions characterized by pronounced ischemia, and metabolic energy deficits. A case–control study of 18 subjects with a history of RVO as well as six healthy volunteers is presented. Serum Nampt levels were quantified using a commercially available enzyme-linked immunosorbent assay kit. Serum Nampt levels were 79% lower in patients with a history of RVO compared with that in healthy volunteers (P<0.05). There was no statistically significant difference among the types of RVOs, specifically branch retinal vein occlusions (n=7), central retinal vein occlusions (n=5), hemiretinal vein occlusions (n=3), and central retinal artery occlusions (n=3; P=0.69). Further studies are needed to establish the temporal kinetics of Nampt expression and to determine whether Nampt may represent a novel biomarker to identify at-risk populations, or whether it is a druggable target with the potential to ameliorate the long-term complications associated with the condition, ie, macular edema, macular ischemia, neovascularization, and permanent loss of vision.
Keywords: Nampt, PBEF, visfatin, nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing factor, retinal artery occlusion, retinal vein occlusion, biomarker, retina, vasculature
Retinal vascular occlusions (RVOs) can present as retinal vein occlusions or retinal artery occlusions and are common causes of irreversible vision loss.1 These occlusions can include either the central retinal vein or artery (CRVO or CRAO) or a branch vessel (BRVO or BRAO).1 Of these, retinal vein occlusions are the most common and also are a common cause of retinal vascular disease, second only to diabetic retinopathy.2 RVOs are prevalent in about 0.5% of the population, with an increased prevalence with increasing age, and some variance in terms of race and ethnicity.3 About half of these cases occur in patients older than 65 years of age, and more than half of these cases are found in patients with cardiovascular diseases such as hypertension, diabetes mellitus, and dyslipidemia. Compromised retinal venous outflow due to intraocular pressure, such as seen in open-angle glaucoma, can produce stasis, predisposing to RVOs.4
Vision loss in RVOs is most commonly caused by macular edema.5 Obstruction within blood vessels leads to serious exudation and, subsequently, macular edema. Permanent edema can lead to degeneration and changes such as subsequent macular edema and epiretinal membranes, ultimately resulting in vision loss.2 Similarly, retinal ischemia increases the release of vascular endothelial growth factors (VEGFs), causing retinal neovascularization, which may in turn lead to retinal hemorrhage or glaucoma secondary to neovascularization.6,7
Various treatment options have been explored; however, outcomes remain unsatisfactory. The current “gold standard” of treatment for BRVO is laser photocoagulation, which has been shown to reduce the risk of vision loss and to improve vision in up to two-thirds of patients with macular edema due to BRVO.8 Various newer treatment options include dexamethasone implants and anti-VEGF therapy, which help decrease central macular thickness, thereby promoting a clinically significant increase in visual acuity.9
However, currently there are no clinically or diagnostically relevant biomarkers that help predict an individual’s risk for developing an RVO or even for disease and therapy outcome. In a first step to identifying novel predictive and diagnostic biomarkers and potential drug targets, we herein quantified the serum levels of Nampt in subjects with RVO and in healthy volunteers.
Nampt as nicotinamide phosphoribosyltransferase functions as an enzyme of critical importance for cellular energy metabolism. In addition, Nampt has been characterized as a proinflammatory cytokine that also possesses neuroprotective properties.10 Besides these physiological functions, Nampt has been correlated with a number of pathological states, including acute lung injury, rheumatoid arthritis, Leber congenital amaurosis,11 and possibly diabetes mellitus (for review, see Sun et al10).
Nampt is the rate-limiting enzyme that catalyzes the first step in the biosynthesis of nicotinamide adenine dinucleotide from nicotinamide (for review, see Imai12). Given the fact that the retina is one of the tissues with the highest energy demand in the body, with most energy derived from oxidative metabolism,13,14 Nampt is a critical metabolic enzyme required for an adequate energy supply. Inhibiting Nampt activity results in detrimental consequences on retinal energy metabolism and in retinal toxicity,11 analogously to mutations in nuclear nicotinamide mononucleotide adenyltransferase (Nampt) in Leber congenital amaurosis.11,15,16
Our results indicate significantly lower circulating Nampt levels in patients with fully resolved RVO compared with the same in healthy volunteers. Our data provide a strong rationale for performing future studies investigating the temporal kinetic profile of Nampt expression, from the acute phase of the RVO through the treatment and resolution phase, to determine the feasibility of using low serum Nampt levels as a novel biomarker for RVOs.
The clinical research presented herein adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board. Subjects were identified in the Eye Clinic at Truman Medical Centers (Kansas City, MO, USA) based on the diagnosis of RVO. We enrolled 18 subjects with a previous diagnosis of RVO and six healthy, age-matched volunteers into our study. The patient demographics are shown in Table 1, and clinical parameters are presented in Table 2. All patients had fully resolved RVO; average time between RVO event and biomarker assessment was 6±2 months. None of the patients had a history of ophthalmological problems before the RVO.
Table 1 Patient demographics (18 eyes of 18 patients)
Table 2 Clinical parameters of subjects with RVOs
For quantification of serum Nampt levels, 13 mL of blood was collected by venipuncture in a BD Vacutainer® venous blood collection tube with clot activator and gel for serum separation (BD, Franklin Lakes, NJ, USA). Serum was prepared according to the manufacturer’s recommendations of inversion and centrifugation. Serum was aliquoted and stored at −80°C until use in experiments.
Enzyme-linked immunosorbent assay
Serum Nampt levels were quantified from subjects’ sera using a commercially available and previously validated assay (Adipogen, San Diego, CA, USA),17 according to the manufacturer’s instructions and using a Synergy H1 plate reader (Biotek, Winooski, VT, USA). Serum samples were tested in triplicates, and the results were validated by quantification using three separate enzyme-linked immunosorbent assay (ELISA) plates. The standard curve was established using a second-order polynomial (quadratic) fit in Prism software v5 (GraphPad Inc, La Jolla, CA, USA), according to the manufacturer’s recommendations, which yielded a goodness of fit of R2=0.9996 (Figure 1A).
Extraction of genomic DNA and single-nucleotide polymorphism analysis
Genomic DNA was extracted from the blood clots remaining after serum separation, essentially as described previously,18 in combination with a commercial DNA extraction kit (QIAamp DNA Blood Maxi Kit, Qiagen Inc, Germantown, MD, USA).
Purity and concentration of genomic DNA were assessed using absorbance at 260, 280, and 320 nm using a NanoVue™ spectrophotometer (GE Healthcare, Little Chalfont, Buckinghamshire, UK). We used molecular beacon technology for the custom designing of single-nucleotide polymorphism (SNP) genotyping probes (sequences are listed in Table 3; Sigma-Aldrich Inc, St Louis, MO, USA) to determine the presence of T1001G and C1535T polymorphisms in the PBEF1 gene. Molecular beacons were labeled with either 6-carboxyfluorescein (6FAM) or hexachloro-6-carboxyfluorescein (HEX) at the 5′-end and with the quencher Black Hole Quencher 1 (BHQ1®) at the 3′-end (Table 3). SNP genotyping was performed using Taqman Universal Mastermix and a StepOne Plus real-time polymerase chain reaction machine (both Applied Biosystems; Life Technologies Inc, Foster City, CA, USA), using 54.5°C as the annealing temperature. Analysis was performed using the SDS software v4 (Applied Biosystems). The probes were validated using a restriction digest approach, as described in Ye et al19 (data not shown). The polymorphisms T1001G and C1535T (originally described as C1543T19) had been identified as predisposing individuals to acute lung injury associated with sepsis.19
Table 3 SNP determination
Data are presented as individual data points on scatter plots; error bars represent the standard error of the mean. Nampt levels were compared between healthy volunteers and subjects with a history of RVO using the Student’s t-test. To compare subtypes of RVOs, we performed one-way analysis of variance (ANOVA) with Tukey’s post hoc test. For correlation analysis, we calculated a Pearson product–moment correlation coefficient (r) to test the strength of the association. All statistical analysis was done in Prism software v5 (GraphPad Inc).
Serum Nampt levels are reduced in RVO
Nampt levels in the sera of control subjects were 0.97±0.16 ng/mL (n=6; Figure 1B, Table 2), in accordance with the published literature.17 In contrast, subjects with a history of RVO had statistically significant reduced Nampt levels (0.20±0.05 ng/mL, n=18, unpaired t-test: P<0.05; Figure 1B, Table 2).
We tested whether different types of RVOs were associated with different Nampt levels. However, in our cohort, we did not identify any statistically significant differences in serum Nampt levels among patients manifesting with hemiretinal vein occlusion (HRVO), BRVO, CRVO, or CRAO (n=19, P=0.69; Figure 1C). However, each type of RVO was significantly different from controls (ANOVA P<0.001; HRVO: n=3, P<0.01; BRVO: n=7, P<0.001; CRVO: n=6, P<0.01; CRAO: n=2, P<0.01; Figure 1C).
When we compared the Nampt levels between the sexes, we did not find any differences between females and males (P=0.11), in accordance with the published literature.20
Furthermore, we correlated the serum Nampt levels with the improvement of visual acuity after the RVO event (Figure 2A), as well as the clinical measurements of retinal thickness derived from spectral-domain optical coherence tomography data (Figure 2B–D) and did not identify any statistically significant associations. There was no statistically significant association between the time since the RVO event and serum Nampt levels (data not shown).
Known confounding factors affecting serum Nampt levels are absent in RVO patients
There are several disease conditions and biometric parameters, including stroke, hepatitis C, and hyperthyroidism, reported in the scientific and medical literature, which show potential correlations with Nampt levels. We, therefore, systematically assessed them within our patient population as potential confounding factors. To determine whether Nampt levels were correlated with age or weight, we calculated a Pearson product–moment correlation coefficient for age and body mass index (BMI). In our cohort, serum PBEF levels did not correlate with age (P=0.75, R2=0.006; Figure 3A) or BMI (P=0.75, R2=0.007; Figure 3B). Similarly, we did not detect any differences among ethnicities (data not shown). For four conditions, namely acute lung injury,19 chronic kidney disease,21 and rheumatoid arthritis22 as well as during chronic hemodialysis,20 serum Nampt levels are being discussed as a reflection of a patient’s inflammation status rather than as a specifically disease-related change. None of the patients in our study suffered from these or related inflammatory disease conditions.
Additional studies have linked SNPs in the PBEF1 gene with a predisposition for worse disease and therapy outcomes in acute lung injury and sepsis.19,23–25 Regarding the disease conditions and biometric parameters affecting serum Nampt levels, we tested the patients’ DNA samples for two known polymorphisms.19 We did not detect the presence of the T1001G or the C1535T polymorphisms in any of our patients (Table 1).
We herein describe low serum Nampt levels in subjects with a history of RVO. To our knowledge, this is the first report of Nampt levels being associated with this disease condition and it represents the identification of the first potential biomarker for RVOs.
The level of serum Nampt in healthy volunteers was in good agreement with the concentrations previously reported.17 Currently, there is significant discrepancy among the different methodologies used to detect Nampt, as described in detail by Korner et al.17 Therefore, we chose a commercially available ELISA assay that has previously been shown to detect Nampt accurately and reproducibly from human serum samples with respect to both epitope specificity and the ability to quantify Nampt over a wide range of concentrations.17 Experimental parameters that we took into consideration were specificity of the antibody, the effect of diluted vs undiluted serum samples, and the fit of the standard curve. Specifically, we validated the Nampt standard using Western blotting and the validated antibody used by Ye et al19 (data not shown). Furthermore, using an in-house-generated recombinant human Nampt protein in the commercial ELISA yielded comparable serum concentrations that were not statistically significantly different from those reported herein using the provided protein standard (data not shown). Diluting the serum sample did not have any effect on quantitative analysis, further indicating the specificity of the antibody. For quantification, we used a second-order polynomial fit, as recommended by the manufacturer. In addition, we ensured that data points fell on the linear portion of the standard curve. Performing linear regression analysis yielded comparable serum Nampt concentrations (data not shown). Overall, our data provide evidence that the ELISA used in the present study resulted in not only high reproducibility but also high specificity for accurately detecting Nampt levels in human serum samples.
To exclude known confounding factors affecting serum Nampt levels from our study’s RVO patient population, we assessed the patients’ medical history, current health status, biometric measures, and genetically predisposing factors associated with the PBEF1 gene. Our experiments did not reveal any differences in Nampt levels between females and males, in accordance with the published literature.20 Furthermore, the role of Nampt in obesity remains unclear. Several studies suggest a direct correlation and role of the protein in obesity development, whereas other studies could not identify any correlation (Stastny et al26 and references therein). The discrepancy among these studies may result from the chosen method for detecting visfatin,17 as well as differences in clinical trial design and statistical power.
Previous studies have identified increases in Nampt serum levels to be associated with acute lung injury,19 chronic kidney disease,21 and rheumatoid arthritis,22 as well as during chronic hemodialysis,20 and it has been suggested that the serum Nampt level in these conditions may reflect the inflammation status rather than a disease-related change.20 In Leber congenital amaurosis, mutations in the nicotinamide adenine dinucleotide (NAD) biosynthesis pathway result in effects reminiscent of decreased Nampt activity.11 Furthermore, SNPs in the PBEF1 gene have been identified as predisposing individuals to worse outcomes after acute lung injury and sepsis.19,23–25 We herein ruled out the two clinically significant polymorphisms, T1001G and C1535T,19 as contributing and/or confounding factors in our patient population.
In the present study, we identified a lower serum Nampt level in subjects with resolved RVOs compared with those in healthy volunteers and healthy control subjects reported in the literature.20
Through its enzymatic activity, Nampt has been shown to exert potent protective effects both in vitro, in cellular models using neurons and cardiac myocytes,27,28 and in vivo, in a middle cerebral artery occlusion model for cerebral ischemia–reperfusion injury and stroke.27–29 Experimental downregulation of Nampt resulted in lower levels of autophagy in animals with cerebral ischemia–reperfusion injury and subsequent poorer outcomes had no effect, however, in the sham condition.29 It is thus perceivable that circulating levels of Nampt correlate with its cellular concentration and thereby its Nampt enzymatic activity level in cells. Similarly, in vitro studies showed that Nampt protected neurons from energy deprivation in neurons using an oxygen–glucose deprivation model.28 Accordingly, small interfering RNA-mediated knockdown of the PBEF gene resulted in increased levels of apoptosis of cardiac monocytes in vitro following glucose deprivation.27
Thus, it can be speculated that subjects with lower systemic levels of Nampt would experience lower levels of cellular Nampt enzyme activity, resulting in reduced endogenous protection from ischemic events that could predispose to and increase the risk for RVOs. Alternatively, the RVO event may prevent normal release of Nampt into the blood stream. Given the different pathophysiology states of retinal vein vs retinal artery occlusions,1 it is notable that patients with both types of occlusion had significantly lower serum Nampt levels that healthy volunteers.
Our results provide an important basis for future studies aimed at identifying whether serum Nampt levels represent a novel risk factor, and hence a potential diagnostic biomarker, for RVOs. Such studies will require a temporal kinetic analysis of serum Nampt levels. Furthermore, our data provide a rationale for devising neuroprotective pharmaceutical strategies targeting an increase in or induction of higher Nampt levels to increase endogenous protection of cells in general, and neurons in particular, in subjects with low circulating Nampt levels, and potentially other at-risk populations, to prevent subsequent deleterious effects on the retina and other metabolically active organs. Such strategies will probably need to consider multiple components of the NAD pathway, given the challenges faced by previous gene therapy approaches targeting NMNAT expression in Leber congenital amaurosis.30
The authors thank Dr Mahendra Rupani for contributing his clinical expertise to this project. The authors thank Margaret, Richard, and Sara Koulen for generous support and encouragement.
Research reported in this publication was supported by grants from the National Eye Institute (EY014227 and EY022774), the Institute on Aging (AG010485, AG022550 and AG027956), and the National Center for Research Resources and National Institute of General Medical Sciences (RR022570 and RR027093) of the National Institutes of Health (PK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional support by the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research, a Challenge Grant from Research to Prevent Blindness, and the Vision Research Foundation of Kansas City is gratefully acknowledged.
The authors report no conflicts of interest in this work.
Mirshahi A, Feltgen N, Hansen LL, Hattenbach LO. Retinal vascular occlusions: an interdisciplinary challenge. Dtsch Arztebl Int. 2008;105(26):474–479.
Keane PA, Sadda SR. Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab. Clin Ophthalmol. 2011;5:771–781.
Sartori MT, Barbar S, Donà A, et al. Risk factors, antithrombotic treatment and outcome in retinal vein occlusion: an age-related prospective cohort study. Eur J Haematol. 2013;90(5):426–433.
Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J. 2008;38(12):904–910.
Sadda S, Danis RP, Pappuru RR, et al. Vascular changes in eyes treated with dexamethasone intravitreal implant for macular edema after retinal vein occlusion. Ophthalmology. 2013;120(7):1423–1431.
Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094.e–1101.e.
Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–809.
Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013;1:CD009510.
Merkoudis N, Granstam E. Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting. Eur J Ophthalmol. 2013;23(4):558–563.
Sun Z, Lei H, Zhang Z. Pre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions. Cytokine Growth Factor Rev. 2013;25(4):433–442.
Zabka TS, Singh J, Dhawan P, et al. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. Toxicol Sci. 2015;144(1):163–172.
Imai S. Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des. 2009;15(1):20–28.
Niven JE, Laughlin SB. Energy limitation as a selective pressure on the evolution of sensory systems. J Exp Biol. 2008;211(pt 11):1792–1804.
Wong-Riley MT. Energy metabolism of the visual system. Eye Brain. 2010;2:99–116.
Falk MJ, Zhang Q, Nakamaru-Ogiso E, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44(9):1040–1045.
Perrault I, Hanein S, Zanlonghi X, et al. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet. 2012;44(9):975–977.
Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007;92(12):4783–4791.
Se Fum Wong S, Kuei JJ, Prasad N, et al. A simple method for DNA isolation from clotted blood extricated rapidly from serum separator tubes. Clin Chem. 2007;53(3):522–524.
Ye SQ, Simon BA, Maloney JP, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med. 2005;171(4):361–370.
Kato A, Odamaki M, Ishida J, Hishida A. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol. 2009;29(1):31–35.
Axelsson J, Witasp A, Carrero JJ, et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49(2):237–244.
Senolt L, Kryštůfková O, Hulejová H, et al. The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. Cytokine. 2011;55(1):116–121.
Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC. Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med. 2007;35(5):1290–1295.
Liu Y, Shao Y, Yu B, Sun L, Lv F. Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population. Clin Chem Lab Med. 2012;50(11):1917–1922.
Lee K, Huh JW, Lim CM, Koh Y, Hong SB. Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome. Scand J Infect Dis. 2013;45(10):760–765.
Stastny J, Bienertova-Vasku J, Vasku A. Visfatin and its role in obesity development. Diabetes Metab Syndr. 2012;6(2):120–124.
Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ Res. 2009;105(5):481–491.
Bi J, Li H, Ye SQ, Ding S. Pre-B-cell colony-enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. J Neurochem. 2012;120(2):334–346.
Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 2012;8(1):77–87.
Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013;110(6):E517–E525.
Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4):388–391.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]